Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

MicroPort MedBot (2252 HK): Growth Flash Amid Favorable Momentum with Approvals and Overseas Sales

MicroPort MedBot (2252 HK): UniPath Bronchoscopic System Approval Will Add To The Growth Momentum

MicroPort MedBot (2252 HK): Overseas Markets Shine; Tuomai Drives Growth; Losses Narrow in 1H25

Equity Bottom-Up

Shanghai MicroPort MedBot / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33485:1" rel="noopener">Shanghai MicroPort MedBot Group (2252 HK)</a> recorded revenue of RMB 551.1M for 2025, representing an increase of 114%, and net loss narrowed down narrowed down to RMB 254M in 2025.</li>
<li>Company achieved a milestone breakthrough in commercialisation in overseas markets, recording overseas sales revenue of RMB 400.2M (73% of total revenue), representing a significant increase of 287% YoY.</li>
<li>Approvals of Toumai variants and other products, technology advantages and commercialisation strength has helped the company’s growth momentum to gain pace and eventually it will bring it back to black.</li>
</ul>



Shanghai MicroPort MedBot Group (2252 HK) recorded revenue of RMB 551.1M for 2025, representing an increase of 114%, and net loss narrowed down narrowed down to RMB 254M in 2025.
Company achieved a milestone breakthrough in commercialisation in overseas markets, recording overseas sales revenue of RMB 400.2M (73% of total revenue), representing a significant increase of 287% YoY.
Approvals of Toumai variants and other products, technology advantages and commercialisation strength has helped the company’s growth momentum to gain pace and eventually it will bring it back to black.


MicroPort MedBot (2252 HK): Toumai Grew by Leaps and Bounds in 2025, Momentum to Sustain Going Ahead